ELMD

AI MemoPost-earnings T+1

Electromed

As of 2026-08-26/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q4/FY2026 results confirmed strong operating momentum • 2026-08-26

Base target: $41 / p=50% prob

Biggest risk

The post-earnings thesis is tempered by CEO succession uncertainty, no quantitative FY2027 guidance, lower FY2026 operating cash flow than the prior year, reimbursement and regulatory exposure, and limited analyst coverage.

Invalidation

Break below $32 or thesis failure.

What would change my mind?

Record revenue and profit growth, expanding operating leverage, $20.5 million of cash, no debt, and sustained bronchiectasis adoption could support continued compounding if the CEO transition is orderly.[#SEC-8K-2026-08-25]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-26

Base target

$41

p=50%

Bull target

$46

p=25%

Bear target

$32

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Thin coverage and target proximity limit near-term upside
Bronchiectasis penetration and sales-force productivity remain the long-term driver
Record revenue and profit growth, expanding operating leverage, $20.5 million of cash, no debt, and sustained bronchiectasis adoption could support continued compounding if the CEO transition is orderly.[#SEC-8K-2026-08-25]

BearKey bullets

CEO retirement and successor-selection risk through April 2027.[#SEC-8K-2026-08-25]
FY2026 operating cash flow declined to $9.7 million from $11.4 million despite higher earnings.[#SEC-8K-2026-08-25]
No quantitative FY2027 guidance was provided in the earnings release, limiting forward visibility.

WatchKey bullets

Q4/FY2026 results confirmed strong operating momentum

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $41 (p=50%)

Target spread vs base: +14% / -22%

Scenario probabilities

Bull Target: $46 (p=25%)Base Target: $41 (p=50%)Bear Target: $32 (p=25%)

Commentary

The earnings print was operationally strong, but forward visibility remains limited because quantitative guidance and a robust post-print analyst-revision set are unavailable. Coverage is thin, social data is absent, and the CEO succession announcement makes this a cautious monitoring setup rather than a high-conviction momentum call.

As of 2026-08-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Thin coverage and target proximity limit near-term upside
Bronchiectasis penetration and sales-force productivity remain the long-term driver

Scenarios

Bull Target (Scenario probability)

$46 / p=25% prob

Base Target (Scenario probability)

$41 / p=50% prob

Bear Target (Scenario probability)

$32 / p=25% prob

Analysis 2026-08-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-26
Q4/FY2026 results confirmed strong operating momentum
The company reported record Q4 revenue of $19.4 million, operating income of $3.8 million, diluted EPS of $0.39, and FY2026 revenue growth of 15.3%. Q4 marked the 15th consecutive quarter of year-over-year revenue and profit growth.[#SEC-8K-2026-08-25]
Prob 75.00% • Move 6.00% • Priced-in 70.00%
EVENT2027-04-02
CEO succession creates an execution and valuation overhang
CEO James Cunniff plans to retire on or about April 2, 2027, and the board has begun a national search. An orderly transition could preserve momentum, but the absence of a named successor adds uncertainty.[#SEC-8K-2026-08-25]
Prob 60.00% • Move -7.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Thin coverage and target proximity limit near-term upside
2026-09-30
Visible analyst coverage is limited, and the packet’s median target is approximately $40 versus the $39.34 anchor price. With no quantitative FY2027 guidance in the earnings release, valuation remains sensitive to any moderation in growth or margins.[#SEC-8K-2026-08-25]
Prob 50% • Move -7% • Priced-in 65%

Long-term Catalysts

Months to a year

Bronchiectasis penetration and sales-force productivity remain the long-term driver
2027-06-30
The investor presentation highlights a large underpenetrated bronchiectasis opportunity, while FY2026 homecare revenue per weighted-average direct sales representative exceeded the company’s target range. Continued adoption, reimbursement execution, and field-force productivity are the main upside path.[#SEC-8K-2026-08-25]
Prob 55% • Move 12% • Priced-in 35%

Risks

CEO retirement and successor-selection risk through April 2027.[#SEC-8K-2026-08-25]
FY2026 operating cash flow declined to $9.7 million from $11.4 million despite higher earnings.[#SEC-8K-2026-08-25]
No quantitative FY2027 guidance was provided in the earnings release, limiting forward visibility.
Recent CEO and CFO open-market sales may weigh on sentiment, but insider transactions are not evidence of operating deterioration.[#SEC-FORM4-2026-06-09][#SEC-FORM4-2026-06-08]
Reimbursement changes, regulatory developments, competition, component costs, and supply-chain pressures could affect results.[#SEC-SEC-8K-2026-08-25]

Peers

Symbol	Summary
BSX	Broader medtech scale and distribution provide a useful quality benchmark, but the comparison does not establish a direct valuation anchor for ELMD.
EW	Large-cap device diversification makes Edwards only an adjacent peer; the contrast reinforces ELMD’s greater execution and concentration sensitivity.
CV	Similar market capitalization but a different medical-device niche, so it is a loose size reference rather than a direct operating comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-26

Loading AI feed…

Symbol

Summary

BSX

Broader medtech scale and distribution provide a useful quality benchmark, but the comparison does not establish a direct valuation anchor for ELMD.

Large-cap device diversification makes Edwards only an adjacent peer; the contrast reinforces ELMD’s greater execution and concentration sensitivity.

Similar market capitalization but a different medical-device niche, so it is a loose size reference rather than a direct operating comparable.